Comparative characteristics of B-type natriuretic peptide expression in the left atrial myocardium in various phenotypes of chronic heart failure and its relationship with plasma NT-proBNP level
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background. Chronic heart failure (CHF) remains a leading cause of hospitalizations and mortality. Measuring blood NT-proBNP concentration is recognized as the “gold standard” for CHF diagnosis. Normally, the atria are considered the primary source of atrial natriuretic peptide (ANP); however, their true contribution to systemic hyperpeptidemia due to B-type natriuretic peptide (BNP) during the progression of various CHF phenotypes and the reduction of left ventricular ejection fraction (LVEF) remains insufficiently studied. Objective. To compare B-type natriuretic peptide (BNP) expression in the left atrial (LA) myocardium across different CHF phenotypes and evaluate its association with plasma level of NT-proBNP. Materials and Methods. In a prospective clinical and morphological study, 75 patients with coronary artery disease after elective coronary artery bypass grafting were examined: comparison group (without clinically manifest CHF, n = 17), CHF with preserved EF (≥ 50 %, n = 20), and a cohort of CHF with reduced/mildly reduced EF (< 50 %, n = 38). BNP expression in LA appendage biopsies was assessed immunohistochemically (percentage of positive cells, H-score). Plasma NT-proBNP levels were determined by ELISA. Results. Plasma NT-proBNP concentrations increased proportionally to the decrease in LVEF: 296.6 pg/mL in the comparison group, 678.8 pg/mL at EF ≥ 50 %, and 1033.2 pg/mL at EF < 50 % (p < 0.001). Meanwhile, tissue BNP expression in the LA remained stable: the percentage of positive cells was 41.5–42.7 %, and the H-score was 64.4–74.3 points (p = 0.139). No significant correlation was found between the LA tissue H-score and plasma NT-proBNP (r = –0.084; p = 0.455). Conclusion. BNP expression in the LA myocardium reaches a functional “atrial plateau” already in coronary artery disease patients without clinical signs of CHF. The lack of increased BNP production in the atria despite the decrease in LVEF indirectly indicates that the ventricular myocardium is the dominant driver of systemic hyperpeptidemia in the manifest stages of the disease.
Source: Translational Medicine
Institution: Bashkir State Medical University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7233788972
